Exagen Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Exagen Stock Summary

Exagen competes with Fonar, Burning Rock, Sera Prognostics, Castle Biosciences, and Sotera Health. Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Exagen operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 219 people.

Exagen Key Financial Ratios

Exagen Key Balance Sheet Accounts

Exagen Key Income Statement Accounts

Exagen Key Cash Accounts

Exagen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Exagen's current stock value. Our valuation model uses many indicators to compare Exagen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Exagen competition to find correlations between indicators driving Exagen's intrinsic value. More Info.Exagen Inc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Exagen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Exagen's earnings, one of the primary drivers of an investment's value.

Exagen Inc Systematic Risk

Today, most investors in Exagen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Exagen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Exagen growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Exagen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Exagen Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Exagen Inc based on widely used predictive technical indicators. In general, we focus on analyzing Exagen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Exagen's daily price indicators and compare them against related drivers.

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.